Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 8/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CXCR6 | O00574 | 1/20 | 0.46 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1787304 | 0.84 | MCHR1 (0.49) | MCHR1KMT2AKDM4EALDH1A1CXCR6 | |
| SCHEMBL1789399 | 0.77 | MCHR1 (0.76) | MCHR1KMT2AACHEMEN1 | |
| SCHEMBL1787153 | 0.77 | SSTR5 (0.55) | MCHR1KMT2AKDM4EALDH1A1CXCR6 | |
| SCHEMBL1789890 | 0.75 | MCHR1 (0.53) | MCHR1KMT2AKDM4EALDH1A1SSTR5 | |
| SCHEMBL1784905 | 0.74 | SOS1 (0.59) | MCHR1KMT2ASSTR5ACHEMEN1 | |
| SCHEMBL3134120 | 0.72 | MCHR1 (0.70) | MCHR1 | |
| SCHEMBL1788208 | 0.71 | MCHR1 (0.79) | MCHR1SSTR5 | |
| SCHEMBL1787608 | 0.70 | SSTR5 (0.58) | MCHR1SSTR5ACHE | |
| SCHEMBL12614652 | 0.70 | SSTR5 (0.58) | MCHR1KMT2AKDM4EALDH1A1SSTR5 | |
| SCHEMBL1787246 | 0.70 | MCHR1 (0.54) | MCHR1KMT2AKDM4EALDH1A1SSTR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124674-A1 | 5/5-OR 5/6-MEMBERED CONDENSED RING CYCLOALKYLAMINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-05-26 | — | — | US | disclosed |
| EP-2319841-A1 | (5-MEMBERED)-(5-MEMBERED) OR (5-MEMBERED)-(6-MEMBERED) FUSED RING CYCLOALKYLAMINE DERIVATIVE | MSD K.K. (JP) | 2011-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124674-A1 | 5/5-OR 5/6-MEMBERED CONDENSED RING CYCLOALKYLAMINE DERIVATIVE | MCHR1, MC5R, MCHR2 | MCHR1 1/4885KMT2A 1001/4885KDM4E 3364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.